Search Patents
  • ADENOVIRUS PARTICLES HAVING A CHIMERIC ADENOVIRUS SPIKE PROTEIN, USE THEREOF AND METHODS FOR PRODUCING SUCH PARTICLES
    Publication number: 20110189234
    Abstract: The present invention is concerned with means and methods for producing adenovirus particles comprising a chimeric adenovirus spike protein that essentially lacks a functional knob domain. One aspect of the invention is concerned with a method for producing adenovirus particles comprising providing cells that are permissive for adenovirus replication with an adenovirus vector, with nucleic acid encoding said chimeric adenovirus spike protein and with nucleic acid encoding at least one adenovirus E3 region protein or a functional part, derivative and/or analogue thereof, said method further comprising culturing said permissive cells to allow for at least one replication cycle of said adenovirus virus and harvesting said adenovirus particle.
    Type: Application
    Filed: February 13, 2007
    Publication date: August 4, 2011
    Inventors: Victor Willem Van Beusechem, Frederik Hubertus Emanuel Schagen
  • Anti COVID-19 Therapies targeting nucleocapsid and spike proteins
    Publication number: 20230302121
    Abstract: Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises comprises a recombinant entity. The recombinant entity comprises a nucleic acid that encodes a nucleocapsid protein of coronavirus 2 (CoV2); and/or wherein the recombinant entity encodes a spike protein of CoV2.
    Type: Application
    Filed: May 4, 2023
    Publication date: September 28, 2023
    Applicant: NantCell, Inc.
    Inventors: Kayvan Niazi, Thomas H. King
  • H52 IBV VACCINE WITH HETEROLOGOUS SPIKE PROTEIN
    Publication number: 20200129614
    Abstract: The present invention relates i.a. to an H52 IBV (infectious bronchitis virus) encoding for a heterologous S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said H52 IBV encoding for a heterologous S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.
    Type: Application
    Filed: October 28, 2019
    Publication date: April 30, 2020
    Inventors: Annika KRAEMER-KUEHL, Egbert Siegfried MUNDT, Hans-Christian PHILIPP
  • Methods and compositions for chimeric coronavirus spike proteins
    Patent number: 9884895
    Abstract: The present invention provides compositions and methods comprising a chimeric coronavirus spike protein.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: February 6, 2018
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Ralph Baric, Sudhakar Agnihothram, Boyd Yount
  • 4/91 IBV VACCINE WITH HETEROLOGOUS SPIKE PROTEIN
    Publication number: 20200129613
    Abstract: The present invention relates i.a. to a 4/91 IBV (infectious bronchitis virus) encoding for a heterologous S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said 4/91 IBV encoding for a heterologous S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.
    Type: Application
    Filed: October 28, 2019
    Publication date: April 30, 2020
    Inventors: Annika KRAEMER-KUEHL, Hans-Christian PHILIPP
  • METHOD AND PLATFORM FOR ENHANCING DETECTION ACTIVITY OF INTERACTION BETWEEN SPIKE PROTEIN RECEPTOR BINDING DOMAIN OF CORONAVIRUS FROM SPECIMEN AND HUMAN ANGIOTENSIN-CONVERTING ENZYME II
    Publication number: 20220412959
    Abstract: The present disclosure provides a method and a platform for enhancing detection activity of an interaction between a spike protein receptor binding domain of coronavirus from a specimen and a human angiotensin-converting enzyme II. The method and the platform of the present disclosure use a cleavable luciferase as a report test for the combination of the spike protein receptor binding domain of coronavirus (such as novel coronavirus) and angiotensin-converting enzyme II. Screening is carried out at the cellular level. The strength of the drug's influence on the interaction between the two molecules can be judged by the strength of the luminescence signal. The detection time can be completed within 20 minutes.
    Type: Application
    Filed: October 19, 2021
    Publication date: December 29, 2022
    Inventors: Hui-Ching Wang, Tian-Neng Li
  • 4/91 IBV vaccine with heterologous spike protein
    Patent number: 11224649
    Abstract: The present invention relates i.a. to a 4/91 IBV (infectious bronchitis virus) encoding for a heterologous S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said 4/91 IBV encoding for a heterologous S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: January 18, 2022
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Annika Kraemer-Kuehl, Hans-Christian Philipp
  • H52 IBV vaccine with heterologous spike protein
    Patent number: 11696947
    Abstract: The present invention relates i.a. to an H52 IBV (infectious bronchitis virus) encoding for a heterologous S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said H52 IBV encoding for a heterologous S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: July 11, 2023
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Annika Kraemer-Kuehl, Egbert Siegfried Mundt, Hans-Christian Philipp
  • Method of Treating or Preventing Clinical Signs Caused by Infectious Bronchitis Virus with 4/91 IBV Vaccine having Heterologous Spike Protein
    Publication number: 20220265815
    Abstract: The present invention relates i.a. to a 4/91 IBV (infectious bronchitis virus) encoding for a heterologous S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said 4/91 IBV encoding for a heterologous S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.
    Type: Application
    Filed: December 8, 2021
    Publication date: August 25, 2022
    Inventors: Annika KRAEMER-KUEHL, Hans-Christian PHILIPP
  • Producing recombinant SARS-CoV-2 spike protein in a pre-fusion state
    Patent number: 11020474
    Abstract: Disclosed is producing recombinant SARS-CoV-2 spike protein in a pre-fusion state, using furin knock out or knockdown mammalian cells (such as HEK293, CHO or other mammalian cells). The pre-fusion state SARS-CoV-2 spike protein can be used as an antigen to generate antibodies/binding molecules for use in SARS-CoV-2 detection assays or in diagnosis of active or prior infection with SARS-CoV-2; as a therapeutic to interfere with SARS-CoV-2 cellular binding; to generate antibodies/binding molecules to SARS-CoV-2 for use in therapy; or, as a vaccine for generating immunity to SARS-CoV-2; or for prophylactic or therapeutic use against related coronaviruses.
    Type: Grant
    Filed: August 25, 2020
    Date of Patent: June 1, 2021
    Inventors: Yang Xiang, Jun Li
  • Method of treating or preventing clinical signs caused by infectious bronchitis virus with 4/91 IBV vaccine having heterologous spike protein
    Patent number: 11744888
    Abstract: The present invention relates i.a. to a 4/91 IBV (infectious bronchitis virus) encoding for a heterologous S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said 4/91 IBV encoding for a heterologous S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.
    Type: Grant
    Filed: December 8, 2021
    Date of Patent: September 5, 2023
    Inventors: Annika Kraemer-Kuehl, Hans-Christian Philipp
  • ANTIBODY THAT BINDS SPECIFICALLY TO THE SARS COV 2 SPIKE PROTEIN, AND METHODS FOR ITS MANUFACTURE
    Publication number: 20230192813
    Abstract: The present invention relates to an antibody that binds specifically to the SARS CoV-2 spike protein, and methods for its manufacture.
    Type: Application
    Filed: May 18, 2021
    Publication date: June 22, 2023
    Inventors: Jan WESJOHANN, Michael GERRITS, Tonchy UGRINOVIC, Nguyen VAN SA, Andreas MICHELS
  • NANOBODIES DIRECTED TO CORONAVIRUS SPIKE PROTEIN RECEPTOR BINDING DOMAIN AND USES THEREOF
    Publication number: 20230235027
    Abstract: The invention generally relates to VHH domains that specifically bind a severe acute respiratory syndrome coronavirus spike protein receptor binding domain, corresponding expression vectors and host cells, and methods of treatment using such VHH domains.
    Type: Application
    Filed: July 23, 2021
    Publication date: July 27, 2023
    Inventors: David Brody, Thomas J. Esparza
  • MODIFIED BETACORONAVIRUS SPIKE PROTEINS
    Publication number: 20230234992
    Abstract: Betacoronavirus Spike proteins, or fragments thereof, including substitution mutations designed to increase stability, decrease the risk of antibody dependent enhancement, or both; and that are useful in, for example, immunogenic compositions.
    Type: Application
    Filed: June 4, 2021
    Publication date: July 27, 2023
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Marco BIANCUCCI, Joel David KARPIAK, Jason Paul LALIBERTE, Anna Ulrika LOWEGARD, Enrico MALITO, Newton Muchugu WAHOME
  • CHIMERIC PROTEIN COMPRISING THE RECEPTOR BINDING DOMAIN OF THE CORONA VIRUS SPIKE PROTEIN AND COMPOSITIONS COMPRISING THEM
    Publication number: 20230405106
    Abstract: The present invention provides a chimeric protein that has a modular structure and comprises a receptor binding domain (RBD) from the spike protein (S) of coronaviruses, a segment able to bind the core antigen from the Hepatitis B Virus (HBcAg), a segment including six consecutive histidine residues (HHHHHH), and two spacer segments. In this chimeric protein the aforementioned segments are arranged in a specific order, and the protein is able to form hybrid nanoparticles with HBcAg. The chimeric protein is part of vaccine compositions used for the prevention of coronavirus infections. Therefore, the invention discloses a method for the prevention of coronavirus infections, whereby a vaccine composition comprising said chimeric protein is administered.
    Type: Application
    Filed: November 3, 2021
    Publication date: December 21, 2023
    Inventors: Glay CHINEA SANTIAGO, Alejandro Miguel MARTÍN DUNN, Diamilé GONZÁLEZ ROCHE, Miladys LIMONTA FERNÁNDEZ, Enrique IGLESIAS PÉREZ, Mónica BEQUET ROMERO, Héctor SANTANA MILIAN, Gabriel J. MARQUEZ PERERA, Alexis MUSACCHIO LASA, Ania CABRALES RICO, Gerardo Enrique GUILLEN NIETO, Marta AYALA ÁVILA, Eulogio PIMENTEL VAZQUEZ, Gertrudis ROJAS DORANTES, Vivian HUERTA GALINDO
  • Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof
    Publication number: 20060110758
    Abstract: The present invention provides methods for locating critical portions or sites on the spike protein (S protein) of SARS-associated coronavirus (SARS-CoV) responsible for the viral infection that causes Severe Acute Respiratory Syndrome (SARS). The present invention also provides new synthetic peptides targeting such critical portions or sites of the S protein of SARS-CoV for preventing or treating of SARS-CoV infection in a subject. The present invention further provides methods of testing antiviral activity exerted by antiviral agents using real-time quantitative PCR.
    Type: Application
    Filed: October 28, 2005
    Publication date: May 25, 2006
    Inventors: Bojian Zheng, Yi Guan, Jiandong Huang, Ming-Liang He
  • SARS-COV-2 SPIKE PROTEIN ANTIBODIES
    Publication number: 20220372114
    Abstract: The present disclosure provides antibodies that bind to the SARS-CoV-2 spike protein, as well as compositions containing the same, and methods of making and using such a composition for treating, preventing, and/or detecting SARS-CoV-2 infection.
    Type: Application
    Filed: May 17, 2022
    Publication date: November 24, 2022
    Inventors: Brian A. ZABEL, Dan LUO, Ling ZHANG, Vydehi KANNEGANTI, Joyce YU, Sophie YANG, Lequn ZHAO, Hua TU
  • NOVEL CORONAVIRUS RECOMBINANT SPIKE PROTEIN, POLYNUCLEOTIDE ENCODING SAME, VECTOR COMPRISING POLYNUCLEOTIDE, AND VACCINE FOR PREVENTING OR TREATING CORONAVIRUS INFECTION, COMPRISING VECTOR
    Publication number: 20230293670
    Abstract: The present invention relates to a novel coronavirus recombinant spike protein, a polynucleotide encoding the same, a vector comprising the polynucleotide, and a vaccine for preventing or treating coronavirus infection, comprising the vector. The coronavirus recombinant spike protein of the present invention is stable and thereby not easily decomposed in cells, and effectively activates immune cells thereby resulting in a high antibody production amount and T cell reactivity. It was confirmed that the vector of the present invention exhibits a high antigen expression level and thereby has a high antibody production amount and T cell reactivity, has a long antibody production period and expression period, and does not show liver toxicity. Accordingly, the vector of the present invention can be helpfully used as a vaccine for preventing or treating coronavirus infection.
    Type: Application
    Filed: August 27, 2021
    Publication date: September 21, 2023
    Inventors: Chang-Yuil KANG, Seung-Phil SHIN, Kwang-Soo SHIN, Tae-Gwon OH
  • MUTANT SPIKE PROTEIN EXTENDING THE TISSUE TROPISM OF INFECTIOUS BRONCHITIS VIRUS (IBV)
    Publication number: 20160060303
    Abstract: The present invention provides an infectious bronchitis virus (IBV) spike protein (S protein) which is based on an S protein from an IBV strain with restricted tissue tropism, but which comprises the sequence XBBXBX in the part of the S2 protein corresponding to residues 686 to 691 of the sequence given as SEQ ID No. 2, where B is a basic residue and X is any amino acid; and which comprises at least one of the following amino acid substitutions with reference to the position numbering of SEQ ID NO:2: Leucine (L) to Phenylalanine (F) at position 578 Asparagine (N) to Serine (S) at position 617 Asparagine (N) to Serine (S) at position 826 Leucine (L) to Phenylalanine (F) at position 857 and Isoleucine (I) to Valine (V) at position 1000 such that an IBV virus comprising the S protein has extended tissue tropism. The present invention also provides a virus comprising such an S protein.
    Type: Application
    Filed: May 1, 2014
    Publication date: March 3, 2016
    Inventors: Paul Britton, Erica Bickerton
  • ANTIBODY SPECIFIC TO SPIKE PROTEIN OF SARS-COV-2 AND USES THEREOF
    Publication number: 20230279080
    Abstract: The present disclosure relates to an antibody or antigen-binding fragment thereof that is specific for a spike protein of SARS-CoV-2. The present disclosure also relates to a pharmaceutical composition for treating and/or preventing diseases and/or disorders caused by a coronavirus in a subject in need thereof, and a method for detecting a coronavirus in a sample.
    Type: Application
    Filed: December 27, 2022
    Publication date: September 7, 2023
    Inventors: Kuo-I LIN, Chi-Huey WONG, Szu-Wen WANG, Yi-Hsuan CHANG
Narrow Results

Filter by US Classification